Indication
biomarker
3 clinical trials
3 products
Clinical trial
Imapct of bioMarkers on Pharmacodynamics and Bleeding Risk of Direct Oral AntiCoagulants and Ticagrelor Study II (IMPACT 2)Status: Not yet recruiting, Estimated PCD: 2026-12-01
Clinical trial
Lenvatinib Combined Pembrolizumab as a Second-line Treatment in Advanced Hepatobiliary Tumors: a Single-center, Single-arm, Non-randomized Clinical StudyStatus: Completed, Estimated PCD: 2021-04-01
Product
Lenvatinib + PembrolizumabClinical trial
A Biomarker Exploration Study of Precision Treatment in Ovarian CancerStatus: Active (not recruiting), Estimated PCD: 2028-12-01